Diamedica Inc.
Records under this name other than the patents Diamedica Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 2 patents it holds.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,716,260 | Use of S-adenosylmethionine, vitamin E, and vitamin C for the treatment of oxidative liver injury Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 8,673,964 | Use of Drug Combinations for Treating Insulin Resistance Formerly held In force · High confidence | In force | High confidence | |
| US 8,017,575 | Treatment of insulin resistance by modulating somatostatin using somatostatin receptor antagonists Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 8,063,024 | Use of S-adenosylmethionine, vitamin E, and vitamin C for the treatment of oxidative liver injury and insulin resistance Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 9,616,015 | Formulations of human tissue kallikrein-1 for parenteral delivery and related methods Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 9,364,521 | Human tissue kallikrein 1 glycosylation isoforms Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 9,839,678 | Human tissue kallikrein 1 glycosylation isoforms Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 12,329,805 | Dosage forms of tissue kallikrein 1 Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 11,857,608 | Dosage forms of tissue kallikrein 1 Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 7,622,447 | Use of glutathione synthesis stimulating compounds in reducing insulin resistance Formerly held Term ended Term ended Jan 27, 2023 · From the USPTO record | Term ended | Term ended Jan 27, 2023 | From the USPTO record |